Prostate Cancer Clinical Trial

Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification

Summary

This study evaluates how new magnetic resonance imaging (MRI) and artificial intelligence techniques improve the image quality and quantitative information for future prostate MRI exams in patients with suspicious of confirmed prostate cancer. The MRI and artificial intelligence techniques developed in this study may improve the accuracy in diagnosing prostate cancer in the future using less invasive techniques than what is currently used.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. To develop and evaluate quantitative dynamic contrast-enhanced (DCE)-MRI analysis techniques that minimize patient- and scanner-specific variabilities in the calculation of quantitative parameters.

II. To develop and evaluate diffusion weighted imaging (DWI) methods that reduce prostate geometric distortion due to patient- and scanner-specific susceptibility and eddy current effects.

III. To develop and evaluate multi-class deep learning models that systematically integrate quantitative multi-parametric (mp)-MRI features for accurate detection and classification of clinically significant prostate cancer (csPCa).

OUTLINE:

RETROSPECTIVE: Patients' medical records are reviewed.

PROSPECTIVE: Patients undergo additional 3 Tesla (T) MRI imaging over 30 minutes before, during, or after their standard of care 3T MRI for a total of 1.5 hours.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male patients 18 years of age and older
Clinical suspicion of prostate cancer or biopsy-confirmed prostate cancer
Undergone or undergoing multi-parametric 3 T prostate MRI at the University of California at Los Angeles (UCLA)
Ability to provide consent

Exclusion Criteria:

Contraindications to MRI (e.g., cardiac devices, prosthetic valves, severe claustrophobia)
Contraindications to gadolinium contrast-based agents other than the possibility of an allergic reaction to the gadolinium contrast-based agent
Prior radiotherapy

Study is for people with:

Prostate Cancer

Estimated Enrollment:

275

Study ID:

NCT04765150

Recruitment Status:

Recruiting

Sponsor:

Jonsson Comprehensive Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

UCLA / Jonsson Comprehensive Cancer Center
Los Angeles California, 90095, United States More Info
Nashla Barroso
Contact
310-794-7952
[email protected]
Kyung H. Sung, PhD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

275

Study ID:

NCT04765150

Recruitment Status:

Recruiting

Sponsor:


Jonsson Comprehensive Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.